Heyholder
‹ Activism Filings

Icure Pharmaceutical Incorporation Q3 profit from the main business KRW 3.7 billion, turning profitable from a loss a year earlier

Icure Pharmaceutical Incorporation· Periodic Report

AI summary · Not investment advice

iCure sold KRW 35.2 billion worth in Q3 and made KRW 3.7 billion from its main business, turning profitable from a loss a year earlier and up 54.4% from the previous quarter.

Operating profit · 3 months

KRW 3.7 billion

Key facts

Revenue (3 months)
KRW 35.2 billion
Net income (3 months)
KRW 2.3 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 20.0 billion
Revenue (year to date)
KRW 105.0 billion
Operating profit (prior-year 3 months)
KRW -2.9 billionLoss
Operating profit (year to date)
KRW 6.3 billion
Net income (prior-year 3 months)
KRW -3.9 billionLoss
Net income (year to date)
KRW 3.9 billion

Commentary

AI commentary · Not investment advice

What happened

Aikyure reported its consolidated results for the third quarter of 2026. Sales for the 3 months were KRW 35.18 billion. That is 75.5% more than the same 3 months a year earlier (KRW 20.04 billion). It is 6.6% lower than the previous quarter.

In the company's terms

Operating profit (profit from the core business) for the 3 months was KRW 3.70 billion. A year earlier the company had an operating loss of KRW 2.91 billion, so it turned to a profit. It is 54.4% higher than the previous quarter.

What changes for shareholders

Net income (final profit after taxes and all other costs) for the 3 months was KRW 2.26 billion. A year earlier it was a loss of KRW 3.87 billion, so it also turned to a profit. It is 0.1% lower than the previous quarter.

For the year to date (January 1 to September 30), sales were KRW 105.03 billion. Operating profit was KRW 6.30 billion. Net income was KRW 3.85 billion.

Comments

No comments yet

Comments from shareholders will appear here.